Something old, something new: Revisiting natural products in Antibiotic drug discovery

Canadian Journal of Microbiology

Volumn 60, Issue 3, 2014, Pages 147-154

  Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Actinomycetes; Antibiotic; Genome; Synthetic biology

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM; GENERIC DRUG; GLYCOPEPTIDE; LINCOSAMIDE; LIPOPEPTIDE; MACROLIDE; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE; TRASTUZUMAB;

ANTIBIOTICS; BIOINFORMATICS; DRUG; GENOME; HEALTH CARE; NATURAL SELECTION; PHARMACEUTICAL INDUSTRY;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL MEMBRANE; CHEMICAL MODIFICATION; CLOSTRIDIUM DIFFICILE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG PURIFICATION; FUNGUS; IN VITRO STUDY; METABOLITE; MOLECULAR WEIGHT; NATURAL SELECTION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STREPTOMYCES CLAVULIGERUS; STREPTOMYCES COELICOLOR; SYNTHETIC BIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOFILMS; BIOLOGICAL EVOLUTION; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LEGISLATION, DRUG; UNITED STATES; VIRULENCE FACTORS;

EID: 84896818567     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/cjm-2014-0063     Document Type: Article

References (65)

1. Anonymous. 2013. Life expectancy at birth, by sex, by province [online]. Available from http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health26-eng.htm [accessed 15 December 2013].
2. Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., et al. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2: 2006.0008. doi:10.1038/msb4100050.PMID:16738554, 16738553.
3. Bentley, S.D., Chater, K.F., Cerdeno-Tarraga, A.M., Challis, G.L., Thomson, N.R., James, K.D., et al. 2002. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature, 417(6885): 141-147. doi:10.1038/417141a. PMID:12000953.
4. Berdy, J. 2005. Bioactive microbial metabolites. J. Antibiot. (Tokyo), 58(1): 1-26. doi:10.1038/ja.2005.1. PMID:15813176.
5. Bister, B., Bischoff, D., Strobele, M., Riedlinger, J., Reicke, A., Wolter, F., et al. 2004. Abyssomicin C-A polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway. Angew. Chem. Int. Ed. Engl. 43(19): 2574-2576. doi:10.1002/anie.200353160. PMID:15127456.
6. Blin, K., Medema, M.H., Kazempour, D., Fischbach, M.A., Breitling, R., Takano, E., and Weber, T. 2013. antiSMASH 2.0 - a versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res. 41(Web Server issue): W204-W212. doi:10.1093/nar/gkt449. PMID:23737449.
7. Breton, R.C., and Reynolds, W.F. 2013. Using NMR to identify and characterize natural products. Nat. Prod. Rep. 30(4): 501-524. doi:10.1039/c2np20104f.PMID:23291908.
8. Brown, E.D. 2013. Is the GAIN Act a turning point in new antibiotic discovery? Can. J. Microbiol. 59(3): 153-156. doi:10.1139/cjm-2013-0089. PMID:23540332.
9. Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., et al. 2008. eSGA: E. coli synthetic genetic array analysis. Nat. Methods, 5(9): 789-795. doi:10.1038/nmeth.1239. PMID:18677321.
10. Caliendo, A.M., Gilbert, D.N., Ginocchio, C.C., Hanson, K.E., May, L., Quinn, T.C., et al. 2013. Better tests, better care: improved diagnostics for infectious diseases. Clin. Infect. Dis. 57(Suppl. 3): S139-S170. doi:10.1093/cid/cit578. PMID:24200831.
11. Challis, G.L. 2014. Exploitation of the Streptomyces coelicolor A3(2) genome sequence for discovery of new natural products and biosynthetic pathways. J. Ind. Microbiol. Biotechnol. 41(2): 219-232. doi:10.1007/s10295-013-1383-2.PMID:24322202.
12. Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., et al. 2010. The genetic landscape of a cell. Science, 327(5964): 425-431. doi:10.1126/science.1180823. PMID:20093466.
13. Craney, A., Ozimok, C., Pimentel-Elardo, S.M., Capretta, A., and Nodwell, J.R. 2012. Chemical perturbation of secondary metabolism demonstrates important links to primary metabolism. Chem. Biol. 19(8): 1020-1027. doi:10.1016/j.chembiol.2012.06.013. PMID:22921069.
14. Craney, A., Ahmed, S., and Nodwell, J. 2013. Towards a new science of secondary metabolism. J. Antibiot. (Tokyo), 66(7): 387-400. doi:10.1038/ja.2013.25. PMID:23612726.
15. D'Costa, V.M., McGrann, K.M., Hughes, D.W., and Wright, G.D. 2006. Sampling the antibiotic resistome. Science, 311(5759): 374-377. doi:10.1126/science. 1120800. PMID:16424339.
16. Delcour, A.H. 2009. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta, 1794(5): 808-816. doi:10.1016/j.bbapap.2008.11.005.PMID:19100346.
17. Drawz, S.M., and Bonomo, R.A. 2010. Three decades of _-lactamase inhibitors. Clin. Microbiol. Rev. 23(1): 160-201. doi:10.1128/CMR.00037-09. PMID:20065329.
18. Eisenstein, B.I., Oleson, F.B., Jr., and Baltz, R.H. 2010. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin. Infect. Dis. 50(Suppl. 1): S10-S15. doi:10.1086/647938. PMID:20067387.
19. Ejim, L., Farha, M.A., Falconer, S.B., Wildenhain, J., Coombes, B.K., Tyers, M., et al. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7(6): 348-350. doi:10.1038/nchembio.559. PMID:21516114.
20. Farha, M.A., Leung, A., Sewell, E.W., D'Elia, M.A., Allison, S.E., Ejim, L., et al. 2013. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem. Biol. 8(1): 226-233. doi:10.1021/cb300413m. PMID:23062620.
21. Felise, H.B., Nguyen, H.V., Pfuetzner, R.A., Barry, K.C., Jackson, S.R., Blanc, M.P., et al. 2008. An inhibitor of Gram-negative bacterial virulence protein secretion. Cell Host Microbe, 4(4): 325-336. doi:10.1016/j.chom.2008.08.001. PMID:18854237.
22. Firn, R. 2011. Nature's chemicals: the natural products that shaped our world. Oxford University Press, Oxford, UK.
23. He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D.J., Martin, M.J., et al. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45(1): 109-113. doi:10.1038/ng.2478. PMID:23222960.
24. Hughes, C.C., and Fenical, W. 2010. Antibacterials from the sea. Chemistry, 16(42): 12512-12525. doi:10.1002/chem.201001279. PMID:20845412.
25. Hung, D.T., Shakhnovich, E.A., Pierson, E., and Mekalanos, J.J. 2005. Smallmolecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science, 310(5748): 670-674. doi:10.1126/science.1116739. PMID:16223984.
26. Ibrahim, A., Yang, L., Johnston, C., Liu, X., Ma, B., and Magarvey, N.A. 2012. Dereplicating nonribosomal peptides using an informatic search algorithm for natural products (iSNAP) discovery. Proc. Natl. Acad. Sci. U.S.A. 109(47): 19196-19201. doi:10.1073/pnas.1206376109. PMID:23132949.
27. Kalan, L., and Wright, G.D. 2011. Antibiotic adjuvants: multicomponent antiinfective strategies. Expert Rev. Mol. Med. 13: e5. doi:10.1017/S1462399410001766.PMID:21342612.
28. Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H., and Elofsson, M. 2003. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10(3): 241-249. doi:10.1016/S1074-5521(03)00046-2. PMID:12670538.
29. Keith, C.T., Borisy, A.A., and Stockwell, B.R. 2005. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4(1): 71-78. doi:10.1038/nrd1609. PMID:15688074.
30. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A.K., Wertheim, H.F., Sumpradit, N., et al. 2013. Antibiotic resistance - the need for global solutions. Lancet Infect. Dis. 13(12): 1057-1098. doi:10.1016/S1473-3099(13)70318-9.PMID:24252483.
31. Lewis, K. 2013. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12(5): 371-387. doi:10.1038/nrd3975. PMID:23629505.
32. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23: 3-25. doi:10.1016/S0169-409X(96)00423-1.
33. McDaniel, R., Thamchaipenet, A., Gustafsson, C., Fu, H., Betlach, M., Ashley, G. 1999. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl. Acad. Sci. U.S.A. 96(5): 1846-1851. doi:10.1073/pnas.96.5.1846. PMID:10051557.
34. McKenzie, N.L., Thaker, M., Koteva, K., Hughes, D.W., Wright, G.D., and Nodwell, J.R. 2010. Induction of antimicrobial activities in heterologous streptomycetes using alleles of the Streptomyces coelicolor gene absA1. J. Antibiot. (Tokyo), 63(4): 177-182. doi:10.1038/ja.2010.13. PMID:20224601.
35. Meyer, D., Sielaff, F., Hammami, M., Bottcher-Friebertshauser, E., Garten, W., and Steinmetzer, T. 2013. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem. J. 452(2): 331-343. doi:10.1042/BJ20130101. PMID:23527573.
36. Moellering, R.C., Jr. 1983. Rationale for use of antimicrobial combinations. Am. J. Med. 75(2A): 4-8. doi:10.1016/0002-9343(83)90088-8. PMID:6351605.
37. Morrison, K.C., and Hergenrother, P.J. 2014. Natural products as starting points for the synthesis of complex and diverse compounds. Nat. Prod. Rep. 31(1): 6-14. doi:10.1039/c3np70063a. PMID:24219884.
38. Nguyen, U.T., Wenderska, I.B., Chong, M.A., Koteva, K., Wright, G.D., and Burrows, L.L. 2012. Small-molecule modulators of Listeria monocytogenes biofilm development. Appl. Environ. Microbiol. 78(5): 1454-1465. doi:10.1128/AEM.07227-11. PMID:22194285.
39. Nielsen, K.F., Mansson, M., Rank, C., Frisvad, J.C., and Larsen, T.O. 2011. Dereplication of microbial natural products by LC-DAD-TOFMS. J. Nat. Prod. 74(11): 2338-2348. doi:10.1021/np200254t. PMID:22026385.
40. Nordqvist, C. 2012. One year on herceptin for breast cancer ideal [online]. Medical News Today, 1 Oct. Available from http://www.medicalnewstoday.com/articles/250912.php [accessed 10 December 2013].
41. O'Brien, J., and Wright, G.D. 2011. An ecological perspective of microbial secondary metabolism. Curr. Opin. Biotechnol. 22(4): 552-558. doi:10.1016/j.copbio.2011.03.010. PMID:21498065.
42. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1): 29-40. doi:10.1038/nrd2201. PMID:17159923.
43. Perlman, D. 1966. Chemically defined media for antibiotic production. Ann. N.Y. Acad. Sci. 139(1): 258-269. doi:10.1111/j.1749-6632.1966.tb41199.x. PMID:5228536.
44. Potterat, O., and Hamburger, M. 2013. Concepts and technologies for tracking bioactive compounds in natural product extracts: generation of libraries, and hyphenation of analytical processes with bioassays. Nat. Prod. Rep. 30(4): 546-564. doi:10.1039/c3np20094a. PMID:23459784.
45. Rasmussen, L., White, E.L., Pathak, A., Ayala, J.C., Wang, H., Wu, J.H., et al. 2011. A high-throughput screening assay for inhibitors of bacterial motility identifies a novel inhibitor of the Na+-driven flagellar motor and virulence gene expression in Vibrio cholerae. Antimicrob. Agents Chemother. 55(9): 4134-4143. doi:10.1128/AAC.00482-11. PMID:21709090.
46. Shlaes, D.M., and Spellberg, B. 2012. Overcoming the challenges to developing new antibiotics. Curr. Opin. Pharmacol. 12(5): 522-526. doi:10.1016/j.coph.2012.06.010. PMID:22832234.
47. Shlaes, D.M., Sahm, D., Opiela, C., and Spellberg, B. 2013. The FDA reboot of antibiotic development. Antimicrob. Agents Chemother. 57(10): 4605-4607. doi:10.1128/AAC.01277-13. PMID:23896479.
48. Song, J.Y., Jeong, H., Yu, D.S., Fischbach, M.A., Park, H.S., Kim, J.J., et al. 2010. Draft genome sequence of Streptomyces clavuligerus NRRL 3585, a producer of diverse secondary metabolites. J. Bacteriol. 192(23): 6317-6318. doi:10.1128/JB. 00859-10. PMID:20889745.
49. Taylor, P.L., Rossi, L., De Pascale, G., and Wright, G.D. 2012. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7(9): 1547-1555. doi:10.1021/cb300269g. PMID:22698393.
50. Thaker, M.N., and Wright, G.D. 2012. Opportunities for synthetic biology in antibiotics: expanding glycopeptide chemical diversity. ACS Synth Biol. In press. doi:10.1021/sb300092n. PMID:23654249.
51. Thaker, M.N., Wang, W., Spanogiannopoulos, P., Waglechner, N., King, A.M., Medina, R., and Wright, G.D. 2013. Identifying producers of antibacterial compounds by screening for antibiotic resistance. Nat. Biotechnol. 31(10): 922-927. doi:10.1038/nbt.2685. PMID:24056948.
52. Traxler, M.F., Watrous, J.D., Alexandrov, T., Dorrestein, P.C., and Kolter, R. 2013. Interspecies interactions stimulate diversification of the Streptomyces coelicolor secreted metabolome. MBio, 4(4): e00459-13. doi:10.1128/mBio.00459-13. PMID:23963177.
53. Tripathi, A., Schofield, M.M., Chlipala, G.E., Schultz, P.J., Yim, I., Newmister, S.A., et al. 2014. Baulamycins A and B, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in Staphylococcus aureus and Bacillus anthracis. J. Am. Chem. Soc. doi:10.1021/ja4115924. PMID:24401083.
54. Walsh, C.T., and Fischbach, M.A. 2010. Natural products version 2.0: connecting genes to molecules. J. Am. Chem. Soc. 132(8): 2469-2493. doi:10.1021/ja909118a. PMID:20121095.
55. Wang, J., Soisson, S.M., Young, K., Shoop, W., Kodali, S., Galgoci, A., et al. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 441(7091): 358-361. doi:10.1038/nature04784. PMID:16710421.
56. Wang, G., Hosaka, T., and Ochi, K. 2008. Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations. Appl. Environ. Microbiol. 74(9): 2834-2840. doi:10.1128/AEM.02800-07. PMID:18310410.
57. Watrous, J., Roach, P., Alexandrov, T., Heath, B.S., Yang, J.Y., Kersten, R.D., et al. 2012. Mass spectral molecular networking of living microbial colonies. Proc. Natl. Acad. Sci. U.S.A. 109(26): E1743-E1752. doi:10.1073/pnas.1203689109.PMID:22586093.
58. Wenderska, I.B., Chong, M., McNulty, J., Wright, G.D., and Burrows, L.L. 2011. Palmitoyl-DL-carnitine is a multitarget inhibitor of Pseudomonas aeruginosa biofilm development. Chembiochem, 12(18): 2759-2766. doi:10.1002/cbic.201100500. PMID:22045628.
59. Wong, K., Ma, J., Rothnie, A., Biggin, P.C., and Kerr, I.D. 2014. Towards understanding promiscuity in multidrug efflux pumps. Trends Biochem. Sci. 39(1): 8-16. doi:10.1016/j.tibs.2013.11.002. PMID:24316304.
60. Worthington, R.J., Richards, J.J., and Melander, C. 2012. Small molecule control of bacterial biofilms. Org. Biomol. Chem. 10(37): 7457-7474. doi:10.1039/c2ob25835h. PMID:22733439.
61. Yang, J.Y., Sanchez, L.M., Rath, C.M., Liu, X., Boudreau, P.D., Bruns, N., et al. 2013. Molecular networking as a dereplication strategy. J. Nat. Prod. 76(9): 1686-1699. doi:10.1021/np400413s. PMID:24025162.
62. Young, K., Jayasuriya, H., Ondeyka, J.G., Herath, K., Zhang, C., Kodali, S., et al. 2006. Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents Chemother. 50(2): 519-526. doi:10.1128/AAC.50.2.519-526.2006. PMID:16436705.
63. Zakeri, B., and Lu, T.K. 2013. Synthetic biology of antimicrobial discovery. ACS Synth. Biol. 2(7): 358-372. doi:10.1021/sb300101g. PMID:23654251.
64. Zetterstrom, C.E., Hasselgren, J., Salin, O., Davis, R.A., Quinn, R.J., Sundin, C., and Elofsson, M. 2013. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the Gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS One, 8(12): e81969. doi:10.1371/journal.pone.0081969. PMID:24324737.
65. Zlitni, S., Ferruccio, L.F., and Brown, E.D. 2013. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat. Chem. Biol. 9(12): 796-804. doi:10.1038/nchembio.1361. PMID:24121552.